{"entity":{"id":"paper-her2climb-brain-lin-jco-2020","kind":"paper","name":"HER2CLIMB brain metastases analysis: intracranial efficacy and survival with tucatinib","aka":[],"tldr":"Among the HER2CLIMB patients with brain metastases, tucatinib doubled the intracranial response rate, cut the risk of intracranial progression or death by about two thirds and lengthened survival.","summary":"Exploratory analysis of the 291 HER2CLIMB patients with brain metastases at baseline, including 174 with active lesions.\n\nRisk of intracranial progression or death was reduced by 68 percent with tucatinib, median central nervous system progression-free survival was 9.9 versus 4.2 months, intracranial response was 47.3 versus 20.0 percent, and median overall survival was 18.1 versus 12.0 months.","asOf":"2026-09-17","links":[{"label":"J Clin Oncol 2020","url":"https://doi.org/10.1200/JCO.20.00775"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/32468955/"}],"tags":[],"related":[],"cancers":["her2-positive-breast-brain-metastases"],"sections":[],"technologies":[],"targets":[],"drugs":["capecitabine","trastuzumab","tucatinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["her2climb"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jco"],"dependsOn":[],"notes":[],"journal":"Journal of Clinical Oncology","year":2020,"doi":"10.1200/JCO.20.00775","pmid":"32468955","authors":"Lin NU, Borges V, Anders C, et al.","paperType":"rct","findings":["Intracranial objective response 47.3 percent vs 20.0 percent.","Median central nervous system progression-free survival 9.9 vs 4.2 months; median overall survival 18.1 vs 12.0 months."],"whatItMeans":"This analysis is the evidence base for treating active HER2-positive brain metastases with a systemic regimen, sometimes deferring radiotherapy, and for tucatinib's brain-specific labelling.","caveats":["Exploratory subgroup analysis, though prespecified.","Local therapy was permitted at isolated brain progression, which complicates interpretation."],"changedPractice":true,"participants":291},"route":"/key-papers/paper-her2climb-brain-lin-jco-2020/","neighbours":{"cancer":[{"id":"her2-positive-breast-brain-metastases","kind":"cancer","name":"HER2-positive breast cancer with brain metastases","route":"/cancers/her2-positive-breast-brain-metastases/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"},{"id":"tucatinib","kind":"drug","name":"Tucatinib","route":"/drugs/tucatinib/"}],"trial":[{"id":"her2climb","kind":"trial","name":"HER2CLIMB","route":"/trials/her2climb/"}],"journal":[{"id":"jco","kind":"journal","name":"Journal of Clinical Oncology","route":"/journals/jco/"}]}}